GLP-1 Drug NLY01 Protects Against Multiple Sclerosis in Animal Models
The GLP-1 receptor agonist NLY01 delayed onset and reduced severity of experimental multiple sclerosis by suppressing inflammation, blocking immune cell trafficking into the brain, and preventing neuron loss.
Quick Facts
What This Study Found
NLY01 delayed EAE onset and reduced severity in prevention paradigm, inhibited immune cell activation and CNS trafficking, suppressed chemokine production, blocked neurotoxic astrocyte genes, prevented retinal ganglion cell loss, and reduced clinical scores in relapsing-remitting EAE.
Key Numbers
Delayed onset; reduced severity; suppressed splenic immune cells; reduced CNS trafficking; blocked neurotoxic astrocyte genes; prevented RGC loss; reduced relapse in RR-EAE
How They Did This
Preclinical study. Mouse experimental autoimmune encephalomyelitis (EAE) model. Prevention and therapeutic paradigms tested. Immune cell analysis, chemokine profiling, gene expression in optic nerves, and retinal ganglion cell quantification.
Why This Research Matters
MS currently has no approved neuroprotective therapy. GLP-1 drugs that both suppress inflammation and protect neurons could fundamentally change MS treatment by addressing the component that causes permanent disability.
The Bigger Picture
GLP-1 drugs continue to reveal benefits across neurological conditions — from Parkinson's to now MS. Their combined anti-inflammatory and neuroprotective effects make them compelling candidates for neurodegenerative diseases where current treatments only address symptoms.
What This Study Doesn't Tell Us
Mouse EAE model only — human MS is more complex. Prevention paradigm (pre-disease) is less clinically relevant than therapeutic paradigm. NLY01 has not been tested in MS patients. EAE models may not capture all aspects of progressive MS.
Questions This Raises
- ?Will NLY01 or other GLP-1 drugs be effective in human MS clinical trials?
- ?Could GLP-1 drugs help with progressive MS where current treatments fail?
- ?Would combining GLP-1 agonists with existing MS immunotherapies provide additive benefit?
Trust & Context
- Key Stat:
- Dual anti-inflammatory + neuroprotective NLY01 both suppresses the immune attack on myelin AND directly protects neurons from death — addressing the unmet need in MS treatment
- Evidence Grade:
- Moderate evidence: well-designed preclinical study with both prevention and therapeutic paradigms, but limited to mouse EAE models. NLY01 is in clinical development for another neurological condition (Parkinson's).
- Study Age:
- Published 2021. GLP-1 agonists for MS are being investigated further, with NLY01 in clinical development for neurological indications.
- Original Title:
- Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis.
- Published In:
- Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 18(3), 1834-1848 (2021)
- Authors:
- Gharagozloo, Marjan, Smith, Matthew D, Sotirchos, Elias S, Jin, Jing, Meyers, Keya, Taylor, Michelle, Garton, Thomas, Bannon, Riley, Lord, Hannah-Noelle, Dawson, Ted M, Dawson, Valina L, Lee, Seulki, Calabresi, Peter A
- Database ID:
- RPEP-05402
Evidence Hierarchy
Frequently Asked Questions
Could diabetes drugs like Ozempic help with multiple sclerosis?
This study suggests GLP-1 drugs could help MS by both reducing inflammation and protecting neurons. However, this has only been tested in mice. Clinical trials in MS patients would be needed to confirm benefits and determine appropriate dosing.
How is this different from current MS treatments?
Current MS drugs mainly suppress the immune system to slow myelin damage. NLY01 does this too, but also appears to directly protect neurons from dying — addressing the progressive neurodegeneration that current treatments cannot prevent.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05402APA
Gharagozloo, Marjan; Smith, Matthew D; Sotirchos, Elias S; Jin, Jing; Meyers, Keya; Taylor, Michelle; Garton, Thomas; Bannon, Riley; Lord, Hannah-Noelle; Dawson, Ted M; Dawson, Valina L; Lee, Seulki; Calabresi, Peter A. (2021). Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 18(3), 1834-1848. https://doi.org/10.1007/s13311-021-01088-5
MLA
Gharagozloo, Marjan, et al. "Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis.." Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021. https://doi.org/10.1007/s13311-021-01088-5
RethinkPeptides
RethinkPeptides Research Database. "Therapeutic Potential of a Novel Glucagon-like Peptide-1 Rec..." RPEP-05402. Retrieved from https://rethinkpeptides.com/research/gharagozloo-2021-therapeutic-potential-of-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.